AVITA Medical, Inc.

Equities

RCEL

US05380C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 20:59:51 30/05/2024 BST 5-day change 1st Jan Change
9.28 USD +5.33% Intraday chart for AVITA Medical, Inc. +12.90% -32.36%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Avita Medical Shares Rise After FDA Nod For Recell Go System MT
Sector Update: Health Care MT
Avita Medical Receives FDA Premarket Approval Supplement for Recell Go System MT
AVITA Medical, Inc. Announces FDA Approval of RECELL GO CI
Transcript : AVITA Medical, Inc. - Special Call
Cantor Fitzgerald Trims Price Target on Avita Medical to $21 From $22, Maintains Overweight Rating MT
Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target is $9 MT
Avita Medical Widens Q1 Loss as Sales, Marketing Expense Jumps; Shares Up 10% MT
Transcript : AVITA Medical, Inc., Q1 2024 Earnings Call, May 13, 2024
AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024 CI
AVITA Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03 MT
BTIG Research Downgrades Avita Medical to Neutral From Buy MT
Avita Medical Lowers Q1 Revenue Guidance on Slower New Account Approvals MT
AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024 CI
AVITA Medical, Inc.(ASX:AVH) added to S&P/ASX All Ordinaries Index CI
AVITA Medical, Inc.(NasdaqCM:RCEL) added to S&P Biotechnology Select Industry Index CI
AVITA Medical Submits Additional RECELL GO PMA Supplement Information to US FDA MT
Transcript : AVITA Medical, Inc. - Special Call
Piper Sandler Raises Price Target on Avita Medical to $21 From $19, Maintains Overweight Rating MT
Transcript : AVITA Medical, Inc., Q4 2023 Earnings Call, Feb 22, 2024
AVITA Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AVITA Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
Chart AVITA Medical, Inc.
More charts
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.31 AUD
Average target price
35 AUD
Spread / Average Target
+163.03%
Consensus
  1. Stock Market
  2. Equities
  3. RCEL Stock
  4. News AVITA Medical, Inc.
  5. Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target is $9